Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma reported record performance for Q4 and full year 2025 and provided 2026 guidance. The company filed a Recorlev patent infringement lawsuit. First-quarter 2026 financial results showed a 38% year-over-year increase in total revenue, driven by Recorlev. The company raised its full-year 2026 revenue guidance. Xeris is on track to initiate Phase 3 for XP-8121 later in 2026 and completed the expansion of its commercial team in Q1 2026. As of May 8, 2026, the stock price was $6.43.

The provided information does not indicate any explicit demand seasonality for Xeris Biopharma Holdings, Inc.'s products and services.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing ready-to-use therapeutic medicines. The company's portfolio includes Gvoke for severe hypoglycemia, Recorlev for Cushing's syndrome, and Keveyis for primary periodic paralysis. Xeris also has a pipeline of development programs, including XP-8121, a Phase 3-ready treatment for hypothyroidism.

Xeris Biopharma Holdings, Inc. is headquartered in Chicago, Illinois, and primarily focuses on developing and commercializing therapies in the United States.

Xeris Biopharma's brand reputation appears positive, driven by its commitment to improving patient lives through innovative therapies and strong financial performance. Recent positive financial results and advancements in its pipeline enhance its reputation for innovation.

Xeris Biopharma Holdings, Inc. has an ownership structure primarily weighted towards institutional investors, who hold approximately 46.73% to 58.40% of the company's shares. Individuals hold approximately 7.14% of the shares, while insiders hold around 4% to 14.28%.